Ikena Oncology, Inc. announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer. Her addition comes at a pivotal time with the Company?s focus on its clinical programs, IK-930 and IK-595, underscoring Ikena?s commitment to driving innovation in the targeted oncology space. Dr. Germa is an accomplished medical oncologist and clinical development leader with over 25 years of pharmaceutical experience across the spectrum of drug development, from early clinical trials to late phase and registrational studies.

Prior to Ikena, Dr. Germa served as the EVP, Global Medicine Development, and Chief Medical Officer at Transcenta Therapeutics, where she played a pivotal role in shaping strategic goals for the company?s oncology and non-oncology portfolio, ensuring successful execution across all clinical development functions. Previously, Dr. Germa held senior leadership positions at global pharmaceutical companies such as AstraZeneca as Vice President and Head of Oncology Early Development Clinical Group, Bristol Myers Squibb as Development Team Lead for NKTR214, and Novartis where in particular she led the development and registration of KISQALI®, solidifying her reputation as a trailblazer in advancing oncology care in the relentless pursuit of a cure for cancer. Dr. Germa earned her Medical Doctor degree and board certification in medical oncology at the University of Lille, a degree in immunology from the University of Lille and a degree in health economics from Paris Diderot University in France.

Dr. Sergio Santillana will resign from his role as Chief Medical Officer upon Dr. Germa?s appointment and will continue to consult for the Company to ensure a smooth transition of clinical responsibilities and activities to Dr. Germa.